CLAIMS

1. A pharmaceutical composition for preventing or treating human rhinovirus infection or human influenza virus infection, wherein said composition is to be applied to the nasal or oral mucosa, comprising a pharmaceutically acceptable carrier and lactoferrin and lysozyme; wherein said composition does not include sialic acid and/or ICAM-1

~~(i) lactoferrin and soluble ICAM-1;~~

~~(ii) lysozyme and soluble ICAM-1;~~

~~(iii) lactoferrin, lysozyme, and soluble ICAM-1;~~

~~(iv) lactoferrin and lysozyme;~~

~~(v) lactoferrin and sialic acid;~~

~~(vi) lactoferrin, lysozyme, and sialic acid~~

~~(vii) lactoferrin, lysozyme, sialic acid, and a neuraminidase inhibitor; or~~

~~(viii) sialic acid and a neuraminidase inhibitor~~.

~~2. The pharmaceutical composition according to claim 1 comprising lactoferrin and lysozyme.~~

~~3~~2. The pharmaceutical composition according to claim 1, further comprising

(i) one or more of zinc peroxide, copper, and silver,

(ii) carrageenan;

(iii) one or more ingredients selected from the group consisting of marshmallow extract, calendula extract, citrus peel extract, honey extract, rosemary extract, myrrh extract, Helichrysum extract, arrowroot extract, neem oil, vitamin C, vitamin E, and grapefruit seed extract; or

(iv) citrus peel extract.

3~~4~~. The pharmaceutical composition according to claim 1, wherein said composition is in the form of a nasal spray, nasal drops, oral spray, oral rinse, or lozenge.

45. Use of the composition of claim 1 in the manufacture of a medicament for prophylaxis and/or treatment of human rhinovirus infection, wherein the composition is to be administered to the nasal and/or oral mucosa of an individual in need thereof.

56. The use according to claim 45, wherein the nasal and/or oral mucosa of said individual in need thereof has human rhinovirus in contact therewith.

76. Use of the composition of claim 1 in the manufacture of a medicament for the prophylaxis and/or treatment of human influenza virus infection, wherein the composition is to be administered to the nasal and/or oral mucosa of an individual in need thereof.

87. The use according to claim 67, wherein the nasal and/or oral mucosa of said individual in need thereof has human influenza virus in contact therewith.

98. The pharmaceutical composition according to claim 21, comprising from 0.5-5000 µg/mL lactoferrin and from 0.5-5000 µg/mL lysozyme.

109. The pharmaceutical composition according to claim 21, comprising from 0.0025% to 1% by weight lysozyme and from 0.00005% to 1% by weight lactoferrin.

1110. The pharmaceutical composition according to claim 1, wherein said carrier provides a residence time of the composition on the nasal and/or oral mucosa of at least 1 minute.